Our analyses of Oncomine data sets revealed that UCP2 is over-expressed in ovarian, bladder, esophageal, testicular, kidney, colorectal, lung, pancreas and prostate cancers as well as in leukemia (Figure 3-V). This evidence concerns the gene UCP2 and prostate carcinoma.